Novartis today expressed disappointment at the National Institute for Health and Clinical Excellence's preliminary recommendation to not recommend Jakavi for the treatment of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis , post-polycythaemia vera myelofibrosis or post-essential thrombocythaemia ... (more)
http://www.medilexicon.com/medicalnews.php?newsid=256343
http://www.medilexicon.com/medicalnews.php?newsid=256343
No comments:
Post a Comment